An Australian stem cell and regenerative medicine company

February 28, 2024

MST Access update: "Phase 1 DFU trial: initial data very promising; recruitment continues"

View Report

View the MST Access Research Update on Cynata Therapeutics

December 01, 2023

MST Access re-initiates coverage: "Harnessing Stem Cell Potential"

View Report

View the MST Access Research Report on Cynata Therapeutics

November 22, 2021

MST Access Updates Research Coverage on Cynata: “Diabetic foot ulcer trial good to go”.

View Report

View the MST Access Research Update on Cynata Therapeutics

June 11, 2021

MST Access Initiates Research Coverage on Cynata: "Unlocking Stem Cell Therapy Potential"

View Report

View the MST Access Initiation Research Report on Cynata Therapeutics

November 25, 2020

H.C. Wainwright & Co. Company Update: “High-Profile Licensing Deal Underscores Cell Therapy Value; Reiterate Buy”

View Report

View the latest H.C. Wainwright Research Update for Cynata Therapeutics